Dr. McDevitt's research focuses on unraveling the acquired genetic and epigenetic changes that lead to poor prognosis myeloid disorders. The long term goals include:
- Identify underlying pathways of deregulation to ultimately allow effective therapeutic targeting.
- Develop more sensitive and accurate biomarkers that improve diagnostic classification and prognostication and can be used in translational clinical trials.
- Apply these findings in early phase clinical trials for patients with accelerating myeloproliferative disorders and mixed myelodysplastic syndrome/myeloproliferative disorders. Of particular current interest are DNA repair pathways and Parp inhibitors.
Key collaborators include Judith Karp, Keith Pratz, James Herman, Alison Moliterno, Doug Smith, Hetty Carraway, Steve Gore, Cliff Takemoto, Scott Kaufmann (Mayo Clinic), and Jaroslaw Maciejewski (Cleveland Clinic).
- Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP., Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A., Blood, 2011.
- Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR., Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes., Haematologica, 2011.
- Tiu RV, O'Keefe CL, Gondek LP, Huh J, Theil K, Mohamedali A, Advani AS, List A, Sekeres MA, McDevitt MA, Mufti G, Maciejewski JP, Prognostic impact of SNP array karyotyping in Myelodysplastic syndromes and related myeloid malignancies, BLOOD, 2011.